Evidence map›Paper›PMID 37398479›Full record

ArticlebioRxiv : the preprint server for biology2023

Scaling of an antibody validation procedure enables quantification of antibody performance in major research applications.

Riham Ayoubi, Joel Ryan, Michael S Biddle, Walaa Alshafie, Maryam Fotouhi, Sara Gonzalez Bolivar, Vera Ruiz Moleon, Peter Eckmann, Donovan Worrall, Ian McDowell and 9 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 25 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 3 countries.

Riham AyoubiDepartment of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Joel RyanAdvanced BioImaging Facility (ABIF), McGill University, Montreal, Canada.
Michael S BiddleNIHR Respiratory BRC, Department of Respiratory Sciences, University of Leicester, Leicester, UK.
Walaa AlshafieDepartment of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Maryam FotouhiDepartment of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Sara Gonzalez BolivarDepartment of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Vera Ruiz MoleonDepartment of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Peter EckmannDepartment of Neuroscience, UC San Diego, La Jolla, CA, United States of America.
Donovan WorrallDepartment of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Ian McDowellDepartment of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Kathleen SouthernDepartment of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Wolfgang ReintschThe Neuro's Early Drug Discovery Unit (EDDU), Structural Genomics Consortium, McGill University, Montreal, Quebec, Canada.
Thomas M DurcanThe Neuro's Early Drug Discovery Unit (EDDU), Structural Genomics Consortium, McGill University, Montreal, Quebec, Canada.
Claire M BrownAdvanced BioImaging Facility (ABIF), McGill University, Montreal, Canada.
Anita BandrowskiDepartment of Neuroscience, UC San Diego, La Jolla, CA, United States of America.
Harvinder S VirkNIHR Respiratory BRC, Department of Respiratory Sciences, University of Leicester, Leicester, UK.
Aled M EdwardsStructural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
Peter S McPhersonDepartment of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Carl LaflammeDepartment of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Montreal Neurological Institute and Hospital · CAMcGill University · CAUniversity of Leicester · GBUC San Diego Health System · USUniversity of California San Diego · USUniversity of Toronto · CA

Funding

TREAT AD Structural Biology CoreU54AG065187 · NIA · EMORY UNIVERSITY · PI ALLAN I LEVEY · 2019 to 2026
$69.7M
Validation of Antibody Reagents for 15 High Priority AMP-AD TargetsRF1AG057443 · NIA · SAGE BIONETWORKS · PI BRENNAN , PAUL, MANGRAVITE, LARA M · 2017 to 2019
$6.0M
From RRID to Resource Watch: A Knowledgebase of Biomedical Research ResourcesR24GM144308 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Anita ELZBIETA Bandrowski, Jeffrey S. Grethe · 2022 to 2026
$2.9M
Medical Research Council MR/N02074X/1Motor Neurone Disease Association SGC/JAN18/988-797NIA NIH HHS RF1 AG057443NIA NIH HHS U54 AG065187NIGMS NIH HHS R24 GM144308
6 · The paper itself

Abstract

Antibodies are critical reagents to detect and characterize proteins. It is commonly understood that many commercial antibodies do not recognize their intended targets, but information on the scope of the problem remains largely anecdotal, and as such, feasibility of the goal of at least one potent and specific antibody targeting each protein in a proteome cannot be assessed. Focusing on antibodies for human proteins, we have scaled a standardized characterization approach using parental and knockout cell lines (Laflamme et al., 2019) to assess the performance of 614 commercial antibodies for 65 neuroscience-related proteins. Side-by-side comparisons of all antibodies against each target, obtained from multiple commercial partners, demonstrates that:

Indexed as

antibodyantibody characterizationantibody validationopen science

Identifiers

PMID37398479
PMCPMC10312534
OpenAlexW4379208409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.